Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.00.

Separately, Weiss Ratings upgraded Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Evaxion A/S in the fourth quarter worth $38,000. Wesbanco Bank Inc. purchased a new stake in shares of Evaxion A/S during the 4th quarter valued at $48,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Evaxion A/S in the 4th quarter worth $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Evaxion A/S in the 1st quarter worth $112,000. Finally, Renaissance Technologies LLC purchased a new position in Evaxion A/S during the 1st quarter worth $146,000. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion A/S Trading Down 2.8%

EVAX stock opened at $3.15 on Friday. Evaxion A/S has a twelve month low of $2.52 and a twelve month high of $12.15. The stock has a market capitalization of $26.27 million, a price-to-earnings ratio of -2.60 and a beta of 0.29. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. The firm’s fifty day simple moving average is $3.13 and its two-hundred day simple moving average is $3.56.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.